Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo bests single therapy in metastatic RCC

Motzer RJ et al. GU Cancers Symposium Abstract 578

Key clinical point: The combination of atezolizumab and bevacizumab is more efficacious than single-agent sunitinib as first-line therapy for metastatic RCC.

Major finding: Among patients with PD-L1-positive disease, median investigator-assessed progression-free survival was 11.2 months with atezolizumab-bevacizumab and 7.7 months with sunitinib (hazard ratio, 0.74; P = .02).

Data source: A randomized phase 3 trial among 915 patients with treatment-naive advanced or metastatic RCC (IMmotion151 trial).

Disclosures: Dr. Motzer disclosed that he has a consulting or advisory role with Pfizer, Novartis, Eisai, Exelixis, and Merck, and that his institution receives research funding from Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Eisai, Novartis, and Genentech/Roche. The study was sponsored by Genentech/Roche.

Source: Motzer RJ et al. GU Cancers Symposium Abstract 578

Citation:

Motzer RJ et al. GU Cancers Symposium Abstract 578

This Week's Must Reads

New MOC pathway developed by ABIM, ASCO, Alternative to focus on oncology expertise

Survey indicates opioid prescriptions have decreased , Physicians' progress to reverse the nation's opioid epidemic. American Medical Association.

Oncologists sue over Medicare drug pay cut, Community Oncology Alliance v. Office of Management and Budget et al. ​

Gender disparity found in oncology research funding, Zhou CD et al. BMJ Open. 2018 Apr 30. doi: 10.1136/bmjopen-2017-018625

Trump administration rejects ACA lawsuit, Texas v. The United States centers on the individual mandate

Must Reads in Renal Cell Carcinoma

Risk categories predict mRCC survival, Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Access to care linked to better outcomes in black men with prostate cancer, Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.

Prostate cancer before age 55 more likely in black men, Nettey OS et al. AUA 2018 (American Urological Association annual meeting). Abstract MP 21-17.

Statins may affect prostate cancer microenvironment, Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.

Prostate cancer risks higher in smokers, Foerster B et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1071.